The statement “COMT is a major enzyme in dopamine degradation
particularly in prefrontal areas because of a lack of the dopamine
transporter in this region” (Krämer et al., 2007) reflects a common
misconception about the role of this enzyme in catecholamine metabolism.
Most available evidence suggests that both isoforms of COMT are
intracellular. More specifically, the membrane-bound MB-COMT has been
localised to the rough endoplasmatic reticulum, and the soluble S-COMT to
the cytosol and nucleus (Ulmanen et al., 1997). If COMT is inside the cell
the enzyme’s access to synaptic dopamine depends on the availability of a
reuptake mechanism. The lack of dopamine transporter in prefrontal cortex
would thus severely limit the function of COMT if it was not for the
norepinephrine transporter, which also transports dopamine (Horn, 1973)
and has an even higher affinity for dopamine than the dopamine transporter
(Eshlemann et al., 1999; Gu et al., 1994). Further, the reduced number of
dopamine transporters in the prefrontal cortex seems to be overcome by the
higher expression of norepinephrine transporters (Moll et al., 2000).
Recent evidence suggests that dopamine reuptake in prefrontal cortex
indeed depends primarily on the norepinephrine transporter (Morón et al.,
2002).
COMT does seem to play an important role in prefrontal cortex,
judging from the expression of its mRNA, which is higher than in the
striatum (Matsumoto et al., 2003). It is thus tempting to reformulate the
above sentence into “COMT is a major enzyme in prefrontal areas despite a
lack of the dopamine transporter in this region”.
References
Eshlemann AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A
(1999)Characteristics of drug interactions with recombinant biogenic amine
transporters expressed in the same cell type. J Pharmacology and
Experimental Therapeutics
289:877-885.
Gu H, Wall SC, Rudnick G (1994) Stable expression of biogenic amine
transporters reveals differences in inhibitor sensitivity, kinetics, and
ion dependence. J Biol Chem 269:7124-7130.
Horn AS (1973) Structure-activity relations for inhibition of
catecholamine uptake into synaptosomes from noradrenaline and dopaminergic
neurones in rat brain homogenates. Br J Pharmac 47:332-338.
Krämer UM, Cunillera T, Càmara E, Marco-Pallarés J, Cucurell D, Nager
W, Bauer P, Schüle R, Schlös L, Rodrguez-Fornells A, Münte TF (2007) The
impact of catechol-O-methyltransferase and dopamine D4 receptor
genotypes on neurophysiological markers of performance monitoring. J
Neurosci 27:14190-14198.
Matsumoto M, Shannon Weickert C, Akil M, Lipska BK, Hyde TM, Herman
MM, Kleinman JE, Weinberger DR (2003) Catechol O-methyltransferase m-RNA
expression in human and rat brain: evidence for a role in cortical
neuronal function. Neuroscience 116:127-137.
Moll GH, Mehnert C, Wicker M, Bock N, Rothenberger A, Rüther E,
Huether G 2000) Age-associated changes in the densities of presynaptic
monoamine transporters in different regions of the rat brain from early
juvenile life to late adulthood. Develop Br Res 119:251-257.
Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002) Dopamine
uptake through the norepinephrine transporter: evidence from knock-out
mouse lines. J Neurosci 22: 389-395.
Ulmanen I, Peränen J, Tenhunen J, Tilgmann C, Karhunen T, Panula P,
Bernasconi L, Aubry J-P, Lundström K (1997) Expression and intracellular
localization of catechol O-methyltransferase in transfected mammalian
cells. Eur J Biochem 243:452-459.
Claudia Wolf (psp205@bangor.ac.uk) and David E. J. Linden
(d.linden@bangor.ac.uk)
Wolfson Centre for Clinical and Cognitive Neuroscience, School of
Psychology, Bangor University, Bangor LL57 2AS, Wales, U.K.
D.L. is funded by The Wellcome Trust, grant number 077185/Z/05/Z.